SCHEMBL26074232

SCHEMBL26074232

COc1cc(Cl)nc2onc(N)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.46
S1PR1 P21453 3/20 0.39
HSP90AA1 P07900 4/20 0.38
HSP90AB1 P08238 4/20 0.38
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 1/20 0.35
CSF1R P07333 2/20 0.34
KIT P10721 2/20 0.34
FLT1 P17948 2/20 0.34
KDR P35968 2/20 0.34
FLT3 P36888 2/20 0.34
AURKA O14965 1/20 0.34
ROCK2 O75116 1/20 0.34
RPS6KA5 O75582 1/20 0.34
NTRK1 P04629 1/20 0.34
LCK P06239 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27176104 0.82 IDO1 (0.65) IDO1HSP90AA1HSP90AB1ALDH1A1L3MBTL1
SCHEMBL29525253 0.78 IDO1 (0.69) IDO1S1PR1ALDH1A1HPGDHSD17B10
SCHEMBL17498436 0.78 IDO1 (0.69) IDO1S1PR1ALDH1A1HPGDHSD17B10
SCHEMBL25564684 0.77 IDO1 (0.43) IDO1S1PR1ALDH1A1L3MBTL1USP2
SCHEMBL29189522 0.76 MAPT (0.39) IDO1S1PR1ALDH1A1L3MBTL1HSD17B10
SCHEMBL27176094 0.75 HPGD (0.49) IDO1ALDH1A1L3MBTL1USP2HPGD
SCHEMBL27176117 0.74 SMN1; SMN2 (0.40) IDO1ALDH1A1USP2HPGDHSD17B10
SCHEMBL27176100 0.74 HSP90AA1 (0.51) IDO1HSP90AA1HSP90AB1ALDH1A1L3MBTL1
SCHEMBL29189519 0.72 IDO1 (0.43) IDO1ALDH1A1MAPTLCK
SCHEMBL30020374 0.72 IDO1 (0.33) IDO1S1PR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119301096-A Inhibitors of MYST family lysine acetyltransferase 伊索斯泰里克斯公司 2025-01-10 CN disclosed
US-20240254139-A1 FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2024-08-01 US disclosed
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases Isosterix, Inc. 2024-05-07 US disclosed
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases Isosterix, Inc. 2024-05-07 US disclosed
CN-117881677-A Fused isoxazolyl compounds as KAT6Aw inhibitors 奥瑞基尼肿瘤有限公司 2024-04-12 CN disclosed
EP-4341259-A1 FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS Aurigene Oncology Limited (IN) 2024-03-27 EP disclosed
WO-2023192817-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2023-10-05 WO disclosed
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2023-09-28 US disclosed
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2023-09-28 US disclosed
WO-2022243983-A1 FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A IDO1 3316/4885S1PR1 4146/4885HSP90AA1 1912/4885
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases KAT6A, KAT6B, KAT2A IDO1 3316/4885S1PR1 4146/4885HSP90AA1 1912/4885
US-20240254139-A1 FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS KAT6A, KAT6B, KAT2A IDO1 1860/4885S1PR1 4448/4885HSP90AA1 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.